Alexey Smolin

Alexey Smolin

Auto-generated profile, based on publicly available information

Alexey Smolin

Burdenko Main Military Clinical Hospital

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in The Lancet
Verified
Journal Article
Closed access
BBBarbara Ann Burtness
Barbara Ann Burtness
KHKevin J Harrington
Kevin J Harrington
MTMakoto Tahara
Makoto Tahara
GCGilberto de Castro
Gilberto de Castro
APAmanda Psyrri
Amanda Psyrri
JYJeffrey Yorio
Jeffrey Yorio

1 November 2019 in The Lancet
Verified
Journal Article
Closed access
LPLuis Paz-Ares
Luis Paz-Ares
MDMikhail Dvorkin
Mikhail Dvorkin
YCYuanbin Chen
Yuanbin Chen
NRNiels Reinmuth
Niels Reinmuth
KHKatsuyuki Hotta
Katsuyuki Hotta
MWMichael Williamson
Michael Williamson

1 June 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
CECathy Eng
Cathy Eng
TKTae Won Kim
Tae Won Kim
JBJohanna Bendell
Johanna Bendell
GAGuillem Argilés
Guillem Argilés
NTNiall C Tebbutt
Niall C Tebbutt
RYR Young
R Young

17 December 2018 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
NRN.A. Rizvi
N.A. Rizvi
BCB. Chul Cho
B. Chul Cho
NRN. Reinmuth
N. Reinmuth
KLK.H. Lee
K.H. Lee
MAM.-J. Ahn
M.-J. Ahn
SPS. Peters
S. Peters
Background: Durvalumab (D), a human IgG1 mAb against PD-1 and CD80, has shown clinical activity in patients (pts) with non-small cell lung cancer (NSCLC). Tremelimumab (T) is a human IgG2 mAb against CTLA-4. D+T has previously also shown durable responses in metastatic NSCLC (mNSCLC). MYSTIC (NCT02453282) was an open-label, Phase 3 trial of first-line treatment with D vs platinum-based doublet chemotherapy (CT) and D+T vs CT in mNSCLC.

1 June 2014 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
IDIrina Demidova
Irina Demidova
ABAleksei Barinov
Aleksei Barinov
NSNikita Savelov
Nikita Savelov
IGIlia Gagarin
Ilia Gagarin
VGViacheslav Grinevitch
Viacheslav Grinevitch
TOTatiana Obukhova
Tatiana Obukhova
Context.— Echinoderm microtubule-associated proteinlike 4 gene ( EML4 ) and anaplastic lymphoma kinase gene ( ALK ) fusion was shown to be the driver of tumorigenesis in approximately 3% to 5% of patients with non–small cell lung cancer (NSCLC) and is associated with response to inhibition with crizotinib. However, no complete agreement regarding the best diagnostic test for identification of ALK rearrangements has been achieved yet. Objective.— To investigate the concordance, sensitivity, and specificity of immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and reverse transcription–polymerase chain reaction (RT-PCR) for detection of ALK rearrangements. Design.— Thirty-six prospectively tested patients with NSCLC who had adenocarcinoma and 10 ALK -positive samples were included in the study. All samples were tested by IHC (ALK1 clone, 5A4 clone, D5F3 clone), FISH (LSI ALK Break Apart and ALK FISH Probe), and multiplexed RT-PCR. Results.— Immunohistochemistry staining was successful in all samples.. Clone D5F3 showed the best sensitivity and specificity of 100%; clones ALK1 and 5A4 showed sensitivities of 91% with specificity of 100%. Both FISH probes showed concordance with sensitivity and specificity of 100%. Hybridization and RT-PCR were successful in 98% and 93.4% of samples, respectively, with sensitivity of 88% and specificity of 100%. Frequent artifacts leading to misinterpretation were observed with all 3 methodologies. Conclusions.— All 3 methodologies showed good sensitivity, specificity, and concordance, when artifacts were characterized and excluded. However, all ambiguous cases have to be confirmed as ALK rearranged by at least 2 of the 3 methods.

13 April 2019 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
BCB.C. Cho
B.C. Cho
NRN. Reinmuth
N. Reinmuth
KLK.H. Lee
K.H. Lee
MAM.-J. Ahn
M.-J. Ahn
ALA. Luft
A. Luft
NRN.A. Rizvi
N.A. Rizvi
Background: In MYSTIC (NCT02453282), an open-label, Phase 3 trial of first-line D (anti-PD-L1) ± T (anti-CTLA-4) vs CT in mNSCLC, while not statistically significant, a clinically meaningful improvement in overall survival (OS) was seen with D vs CT in pts with tumour cell PD-L1 expression ≥25% (TC ≥25% [primary analysis population]; D vs CT, HR 0.76 [97.54% CI 0.56–1.02], p=0.036; D+T vs CT, HR 0.85 [98.77% CI 0.61–1.17], p=0.202). Here we report OS in clinically relevant pt subgroups and safety results from MYSTIC.